Show simple item record

2011-09-09Zeitschriftenartikel DOI: 10.1371/journal.pone.0023946
Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort.
dc.contributor.authorStoll, Matthias
dc.contributor.authorKollan, Christian
dc.contributor.authorBergmann, Frank
dc.contributor.authorBogner, Johannes
dc.contributor.authorFaetkenheuer, Gerd
dc.contributor.authorFritzsche, Carlos
dc.contributor.authorHoeper, Kirsten
dc.contributor.authorHorst, Heinz-August
dc.contributor.authorLunzen, Jan van
dc.contributor.authorPlettenberg, Andreas
dc.contributor.authorReuter, Stefan
dc.contributor.authorRockstroh, Jürgen
dc.contributor.authorStellbrink, Hans-Jürgen
dc.contributor.authorHamouda, Osamah
dc.contributor.authorBartmeyer, Barbara
dc.date.accessioned2018-05-07T14:51:55Z
dc.date.available2018-05-07T14:51:55Z
dc.date.created2011-09-26
dc.date.issued2011-09-09none
dc.identifier.otherhttp://edoc.rki.de/oa/articles/rekXBsBKodDI/PDF/29L1clnUpGoQ.pdf
dc.identifier.urihttp://edoc.rki.de/176904/959
dc.description.abstractBackground/Aim of the Study: The study aimed to determine the cost impacts of antiretroviral drugs by analysing a longterm follow-up of direct costs for combined antiretroviral therapy, cART,-regimens in the nationwide long-term observational multi-centre German HIV ClinSurv Cohort. The second aim was to develop potential cost saving strategies by modelling different treatment scenarios. Methods: Antiretroviral regimens (ART) from 10,190 HIV-infected patients from 11 participating ClinSurv study centres have been investigated since 1996. Biannual data cART,-initiation, cART-changes, surrogate markers, clinical events and the Centre of Disease Control- (CDC)-stage of HIV disease are reported. Treatment duration was calculated on a daily basis via the documented dates for the beginning and end of each antiretroviral drug treatment. Prices were calculated for each individual regimen based on actual office sales prices of the branded pharmaceuticals distributed by the license holder including German taxes. Results: During the 13-year follow-up period, 21,387,427 treatment days were covered. Cumulative direct costs for antiretroviral drugs of J812,877,356 were determined according to an average of J42.08 per day (J7.52 to J 217.70). Since cART is widely used in Germany, the costs for an entire regimen increased by 13.5%. Regimens are more expensive in the advanced stages of HIV disease. The potential for cost savings was calculated using non-nucleotide-reverse-transcriptaseinhibitor, NNRTI, more frequently instead of ritonavir-boosted protease inhibitor, PI/r, in first line therapy. This calculation revealed cumulative savings of 10.9% to 19.8% of daily treatment costs (50% and 90% substitution of PI/r, respectively). Substituting certain branded drugs by generic drugs showed potential cost savings of between 1.6% and 31.8%. Conclusions: Analysis of the data of this nationwide study reflects disease-specific health services research and will give insights into the cost impacts of antiretroviral therapy, and might allow a more rational allocation of resources within the German health care system.eng
dc.language.isoeng
dc.publisherRobert Koch-Institut, Infektionsepidemiologie
dc.subjectAdulteng
dc.subjectHumanseng
dc.subjectFemaleeng
dc.subjectGermanyeng
dc.subjectMaleeng
dc.subjectCohort Studieseng
dc.subjectHIV Infections/drug therapyeng
dc.subjectReverse Transcriptase Inhibitors/therapeutic useeng
dc.subjectFollow-Up Studieseng
dc.subjectReverse Transcriptase Inhibitors/pharmacologyeng
dc.subjectAnti-HIV Agents/therapeutic useeng
dc.subjectAnti-HIV Agents/economicseng
dc.subjectAnti-HIV Agents/pharmacologyeng
dc.subjectCost Savings/statistics & numerical dataeng
dc.subjectDrug Prescriptions/economicseng
dc.subjectDrug Prescriptions/statistics & numerical dataeng
dc.subjectDrug Therapy Combination/economicseng
dc.subjectDrugs Generic/economicseng
dc.subjectDrugs Generic/pharmacologyeng
dc.subjectDrugs Generic/therapeutic useeng
dc.subjectHIV Reverse Transcriptase/antagonists & inhibitorseng
dc.subjectProtease Inhibitors/economicseng
dc.subjectProtease Inhibitors/pharmacologyeng
dc.subjectProtease Inhibitors/therapeutic useeng
dc.subjectReverse Transcriptase Inhibitors/economicseng
dc.subject.ddc610 Medizin
dc.titleCalculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort.
dc.typeperiodicalPart
dc.identifier.urnurn:nbn:de:0257-10015529
dc.identifier.doi10.1371/journal.pone.0023946
dc.identifier.doihttp://dx.doi.org/10.25646/884
local.edoc.container-titlePLoS ONE
local.edoc.container-textStoll, M., Kollan, C., Bergmann, F., Bogner, J., Faetkenheuer, G., Fritzsche, C., Hoeper, K., Horst, H.-A., van Lunzen, J., Plettenberg, A., Reuter, S., Rockstroh, J., Stellbrink, H.-J., Hamouda, O., Bartmeyer, B. Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv Cohort (2011) PLoS ONE, 6 (9), art. no. e23946
local.edoc.fp-subtypeArtikel
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttp://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0023946
local.edoc.container-publisher-namePublic Library of Science
local.edoc.container-volume6
local.edoc.container-issue9
local.edoc.container-year2011

Show simple item record